Brief: Keros Therapeutics Announces Initial Topline Results From Phase 1 Clinical Trial Of KER-065 In Healthy Volunteers

Keros Therapeutics

31/03/2025 11:04

March 31 (Reuters) - Keros Therapeutics Inc KROS.O:

KEROS THERAPEUTICS ANNOUNCES INITIAL TOPLINE RESULTS FROM PHASE 1 CLINICAL TRIAL OF KER-065 IN HEALTHY VOLUNTEERS

KEROS THERAPEUTICS INC -PLANS ON ADVANCING KER-065 INTO A PHASE 2 CLINICAL TRIAL IN DMD, SUBJECT TO POSITIVE REGULATORY INTERACTION

KEROS THERAPEUTICS INC: PLANS ON ADVANCING KER-065 INTO A PHASE 2 CLINICAL TRIAL IN DMD

KEROS THERAPEUTICS INC: KER-065 WAS GENERALLY WELL-TOLERATED, WITH NO MAJOR SAFETY SIGNALS OBSERVED TO DATE

KEROS THERAPEUTICS: TO INITIATE PHASE 2 CLINICAL TRIAL OF KER-065 IN PATIENTS WITH DMD IN Q1 2026

Source text: ID:nGNX1XjyDG

Further company coverage: KROS.O

 ((Reuters.Briefs@thomsonreuters.com;))